Company intelligence / Profile preview
CellxLife
Los Angeles, California, United Statescellxlife.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
In Phase I trials, 75% of children with metastatic osteosarcoma who responded well to surgery overcame their cancer and are still alive today. 62.5% of all children with metastatic osteosarcoma treated with the therapy lived for over 15 years, compared to typical 5-year survival rates of less than 20%.[1]
- Therapeutic areas
- Oncology
- Modalities
- Dendritic cell-based therapeutic vaccine
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on CellxLife.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellxLife.